GlobeImmune Inc (GBIM)

OTC Markets
0.451
-0.055(-10.88%)
  • Volume:
    7,591
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    0.451 - 0.535

GBIM Overview

Prev. Close
0.506
Day's Range
0.451-0.535
Revenue
-
Open
0.495
52 wk Range
0.099-5.46
EPS
-0.39
Volume
7,591
Market Cap
2.59M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
14,928
P/E Ratio
-
Beta
2.03
1-Year Change
151.06%
Shares Outstanding
5,751,574
Next Earnings Date
-
What is your sentiment on GlobeImmune Inc?
or
Market is currently closed. Voting is open during market hours.

GlobeImmune Inc News

GlobeImmune Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellNeutral
SummaryStrong SellStrong SellStrong SellStrong SellSell

GlobeImmune Inc Company Profile

GlobeImmune Inc Company Profile

Employees
3

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.